ligands acting on targets

(R)-Nepicastat HCl (RS-25560-198), the R-enantiomer of Nepicastat HCl, is a potent and selective inhibitor with IC50 of 25.1 nM and 18.3 nM for bovine and human dopamine-β-hydroxylase, with negligible affinity for twelve other enzymes and thirteen

(R)-Nepicastat HCl.

(R)-NFPS.

(R)-NFPS.

(R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator ( CFTR ) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF).Form:Solid.

(R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator ( CFTR ) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF).Form:Solid.

(R)-Olacaftor ((R)-VX-440) is a Cystic fibrosis transmembrane conductance regulator ( CFTR ) modulator. (R)-Olacaftor has good potential for the study of cystic fibrosis (CF).

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.

(R)-Omeprazole Sodium Salt, the R-Form of Omeprazole. Acts as a gastric proton-pump inhibitor. (R)-Omeprazole Sodium Salt is an inhibitor of ATP4, CYP2C19, CYP2C9 and CYP3A.